Friday, 21 Jul 2017

Unknown content type

Inflammatory and Autoimmune Diseases are Not Rare in HIV Patients

HIV infection and AIDs has been associated with numerous complications, presumeably resulting from impaired immunity from infection.  Sporadic cases and small cohorts of patients with rheumatic and autoimmune syndromes have been described but epidemiology data on the prevalence is scarce.

The RheumNow Week in Review – 21 July 2017

Dr. Jack Cush reviews the news from the past week on RheumNow.com: 

Adverse Maternal and Fetal Outcomes in Lupus - and Pre-Lupus Too

A population-based claim study from Sweden has shown that lupus and pre-lupus patients are at risk for adverse maternal and fetal outcomes.   

Obesity Impairs TNF Inhibitor Responses in Axial Spondyloarthritis

Investigators with the Swiss Clinical Quality Management (SCQM) program have studied the effects of obesity on patients with axial spondyloarthritis (axSpA) and, specifically, their response to tumor necrosis factor inhibitors (TNFi).

CDC: Pneumococcal Vaccination in Adults

Streptococcus pneumonia is a leading cause of morbidity and mortality in adults; including patients with autoimmune diseases who are at particular risk.

In 2014, the ACIP recommended routine use of the 13-valent pneumococcal conjugate vaccine (PCV13) in series with the 23-valent pneumococcal polysaccharide vaccine PPSV23 for adults ≥ 65 years, with the goal of providing broader protection by adding the PCV13 recommendation.

Acute Coronary Syndrome Increased in Early Rheumatoid Arthritis

It does not come as a surprise to anyone anymore that Acute Coronary Syndrome (ACS) is one of the major causes of morbidity and preterm mortality in RA. What we don’t know is what measures need to be taken to modify the risk and how effective such measures are.

This nationwide population-based cohort study addresses the issue of efficacy of treatment options and treatment algorithms in reduction of ACS in RA patients.

Cumulative Genetic Hit Hypothesis for Lupus

A recent report in Nature Communications has studied multiple nationalities has shown a "disentangled complex HLA multigenic effect" underlying the genetic basis of systemic lupus erythematosus (SLE).  (Citation source: http://buff.ly/2u623Ht)

Curbside Consults - July 2017

Curbside Consults are cases submitted by our rheumatology colleagues as challenging therapeutic or safety issues. Answers are based on experience, with added evidence from the medical literature and published guidelines. Here are four new cases. 

Long-Term Additive Cardiovascular Benefit of Plaquenil and Aspirin in Lupus

Systemic lupus erythematosus (SLE) is associated with an increased risk of cardiovascular disease (CVD). The cardioprotective benefits of aspirin (ASA) are well known and the ancillary CV and diabetogenic effects of hydroxychloroquine (HCQ) have also been shown.  A current study in the Journal of Rheumatology has shown that thromboprophylaxis with low-dose ASA and HCQ) yields CVD benefits in SLE.

 

FDA Approves Tremfya (guselkumab) for Plaque Psoriasis

The U.S. Food and Drug Administration (FDA) has approved the IL-23 inhibitor, Tremfya (guselkumab), for patients with moderate to severe plaque psoriasis.

The RheumNow Week in Review – 14 July 2017

Dr. Jack Cush reviews highlights from the past week on RheumNow.com:

Statins Improve Survival in Ankylosing Spondylitis

Systemic inflammation (from underling inflammatory polyarthritis) clearly accelerates atherosclerosis with a resultant increase risk of cardiovascular disease.